Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
2005 1
2007 1
2008 1
2012 1
2013 3
2014 2
2018 2
2019 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome.
Kim YJ, Jung SH, Hur EH, Choi EJ, Lee KH, Yim SH, Kim HJ, Kwon YR, Jeon YW, Lee SH, Chung YJ, Lee JH. Kim YJ, et al. Leuk Res. 2018 Nov;74:97-104. doi: 10.1016/j.leukres.2018.10.004. Epub 2018 Oct 11. Leuk Res. 2018. PMID: 30343213 Clinical Trial.
We investigated the prognostic role of somatic mutations in allogeneic hematopoietic cell transplantation (HCT) for de novo myelodysplastic syndrome (MDS). We performed targeted deep sequencing analysis of 26 genes on bone marrow samples obtained withi …
We investigated the prognostic role of somatic mutations in allogeneic hematopoietic cell transplantation (HCT) for de novo …
Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation.
Kim SY, Le Rademacher J, Antin JH, Anderlini P, Ayas M, Battiwalla M, Carreras J, Kurtzberg J, Nakamura R, Eapen M, Deeg HJ. Kim SY, et al. Haematologica. 2014 Dec;99(12):1868-75. doi: 10.3324/haematol.2014.108977. Epub 2014 Aug 8. Haematologica. 2014. PMID: 25107891 Free PMC article.
There were no significant differences with regard to 5-year probabilities of relapse, non-relapse mortality, relapse-free survival and overall survival; these were 14%, 40%, 46% and 49% for post-aplastic anemia myelodysplastic syndrome, and 20%, 33%, 47% and 49% for de …
There were no significant differences with regard to 5-year probabilities of relapse, non-relapse mortality, relapse-free survival and overa …
Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
Kanagal-Shamanna R, Yin CC, Miranda RN, Bueso-Ramos CE, Wang XI, Muddasani R, Medeiros LJ, Lu G. Kanagal-Shamanna R, et al. Cancer Genet. 2013 Jan-Feb;206(1-2):42-6. doi: 10.1016/j.cancergen.2012.12.005. Epub 2013 Jan 26. Cancer Genet. 2013. PMID: 23357231
Three patients with therapy-related MDS (t-MDS) had a relatively indolent clinical course, whereas two patients presented with AML or developed AML shortly after t-MDS. ...
Three patients with therapy-related MDS (t-MDS) had a relatively indolent clinical course, whereas two patients presented with AML or …
Aberration of p73 promoter methylation in de novo myelodysplastic syndrome.
Zhao Y, Gu S, Guo J, Zhang Z, Zhang X, Li X, Chang C. Zhao Y, et al. Hematology. 2012 Sep;17(5):275-82. doi: 10.1179/1607845412Y.0000000018. Hematology. 2012. PMID: 22971533 Clinical Trial.
However, we failed to find any significant association between p73 methylation and clinical responses to decitabine, a hypomethylating agent that was approved by the US Food and Drug Administration for the treatment of patients with MDS. ...
However, we failed to find any significant association between p73 methylation and clinical responses to decitabine, a hypomethylatin …
The clinical outcomes of haploidentical stem cell transplantation (haplo-HSCT) for patients with therapy-related myelodysplastic syndrome: comparable to de novo myelodysplastic syndrome.
Tang F, Wang Y, Wang Y, Jin J, Han W, Chen Y, Yan C, Xu L, Zhang X, Huang X. Tang F, et al. Clin Exp Med. 2024 Feb 8;24(1):33. doi: 10.1007/s10238-023-01287-8. Clin Exp Med. 2024. PMID: 38329593 Free PMC article.
Therapy-related myelodysplastic syndrome (t-MDS) is defined as a complication in patients with cancer following exposure to chemotherapy and/or radiotherapy and has an inferior outcome compared with de novo myelodysplastic syndrome (de novo MDS). This …
Therapy-related myelodysplastic syndrome (t-MDS) is defined as a complication in patients with cancer following exposure to chemotherapy and …
Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT.
Berger G, Kroeze LI, Koorenhof-Scheele TN, de Graaf AO, Yoshida K, Ueno H, Shiraishi Y, Miyano S, van den Berg E, Schepers H, van der Reijden BA, Ogawa S, Vellenga E, Jansen JH. Berger G, et al. Blood. 2018 Apr 19;131(16):1846-1857. doi: 10.1182/blood-2017-09-805879. Epub 2018 Jan 8. Blood. 2018. PMID: 29311096 Free article. Clinical Trial.
WES identified a significantly higher number of mutations in tMNs as compared with de novo myelodysplastic syndrome (MDS) (median 27 vs 12 mutations; P = .001). ...
WES identified a significantly higher number of mutations in tMNs as compared with de novo myelodysplastic syndrome …
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).
Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott BL, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorror ML, Ehninger G, Deeg HJ. Platzbecker U, et al. Biol Blood Marrow Transplant. 2008 Nov;14(11):1217-25. doi: 10.1016/j.bbmt.2008.08.006. Biol Blood Marrow Transplant. 2008. PMID: 18940675 Free PMC article. Clinical Trial.
The prognosis of patients with de novo myelodysplastic syndrome (MDS) who are red blood cell transfusion-dependent (TD) and receive supportive care is inferior to that of patients who do not require transfusions. ...Our data do not identify TD as an in …
The prognosis of patients with de novo myelodysplastic syndrome (MDS) who are red blood cell transfusion-depende …
Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. Fenaux P, et al. Br J Haematol. 1991 Apr;77(4):497-501. doi: 10.1111/j.1365-2141.1991.tb08616.x. Br J Haematol. 1991. PMID: 2025575
We treated 47 adult patients with de novo myelodysplastic syndrome (MDS) by an anthracycline-AraC regimen. ...
We treated 47 adult patients with de novo myelodysplastic syndrome (MDS) by an anthracycline-AraC regimen. ...
Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients.
Hiramoto N, Kurosawa S, Tajima K, Okinaka K, Tada K, Kobayashi Y, Shinohara A, Inoue Y, Ueda R, Tanaka T, Kim SW, Yamashita T, Heike Y, Fukuda T. Hiramoto N, et al. Eur J Haematol. 2014 Feb;92(2):137-46. doi: 10.1111/ejh.12214. Epub 2013 Nov 9. Eur J Haematol. 2014. PMID: 24127668
14 results